Trends in the eradication rates of Helicobacter pylori infection for eleven years

World Journal of Gastroenterology

Volumn 18, Issue 45, 2012, Pages 6628-6634

  Yoon, Jai Hoon ^a   Baik, Gwang Ho ^a   Sohn, Kyoung Min ^a   Kim, Dae Yong ^a   Kim, Yeon Soo ^a   Suk, Ki Tae ^a   Kim, Jin Bong ^a   Kim, Dong Joon ^a   Kim, Jin Bae ^a   Shin, Woon Geon ^a   Kim, Hak Yang ^a   Baik, Il Hyun ^a   Jang, Hyun Joo ^a  

^a Hallym University College of Medicine   (South Korea)

Author keywords

Clarithromycin; Eradication; Helicobacter pylori; Proton pump inhibitor; Therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE; UREASE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; DIARRHEA; DISEASE ASSOCIATION; DISEASE CONTROL; DUODENUM ULCER; DYSPEPSIA; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; RETROSPECTIVE STUDY; STOMACH BIOPSY; STOMACH ULCER; UREA BREATH TEST;

EID: 84873904009     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i45.6628     Document Type: Article

References (30)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186
2. Lind T, Mégraud F, Unge P, Bayerdörffer E, O'morain C, Spiller R, Veldhuyzen Van Zanten S, Bardhan KD, Hellblom M, Wrangstadh M, Zeijlon L, Cederberg C. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-253
3. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600
4. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825
5. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781
6. Hwang TJ, Kim N, Kim HB, Lee BH, Nam RH, Park JH, Lee MK, Park YS, Lee DH, Jung HC, Song IS. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol 2010; 44: 536-543
7. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009; 54: 269-278
8. Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, Graham DY, Kwon DH. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001; 47: 459-461
9. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007; 56: 475-479
10. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-609
11. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003; 17 Suppl B: 36B-40B
12. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123: 1763-1769
13. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi Porro G. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001; 96: 359-366
14. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107
15. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384
16. Buzás GM. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16: 3865-3870
17. Kim N, Kim JM, Kim CH, Park YS, Lee DH, Kim JS, Jung HC, Song IS. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006; 40: 683-687
18. Fischbach LA, Goodman KJ, Feldman M, Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002; 31: 128-139
19. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153
20. Tanimura H, Kawano S, Kubo M, Abe T, Goto M, Tanabe J, Asai A, Ito T. Does Helicobacter pylori eradication depend on the period of amoxicillin treatment? A retrospective study. J Gastroenterol 1998; 33: 23-26
21. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, Zhang J, Bhattacharyya H, King EC, Hopkins RJ. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136: 13-24
22. Simsek H, Balaban YH, Gunes DD, Hascelik G, Ozarlan E, Tatar G. Alarming clarithromycin resistance of Helicobacter pylori in Turkish population. Helicobacter 2005; 10: 360-361
23. Kalach N, Serhal L, Asmar E, Campeotto F, Bergeret M, Dehecq E, Spyckerelle C, Charkaluk ML, Decoster A, Dupont C, Raymond J. Helicobacter pylori primary resistant strains over 11 years in French children. Diagn Microbiol Infect Dis 2007; 59: 217-222
24. Di Mario F, Cavallaro LG, Scarpignato C. 'Rescue' therapies for the management of Helicobacter pylori infection. Dig Dis 2006; 24: 113-130
25. Chung SJ, Lee DH, Kim N, Jung SH, Kim JW, Hwang JH, Park YS, Lee KH, Jung HC, Song IS. Eradication rates of helicobacter pylori infection with second-line treatment: nonulcer dyspepsia compared to peptic ulcer disease. Hepatogastroenterology 2007; 54: 1293-1296
26. Lee JH, Cheon JH, Park MJ, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS. The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years. Korean J Gastroenterol 2005; 46: 94-98
27. Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idström JP. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1: 138-144
28. Baena Díez JM, López Mompó C, Rams Rams F, García Lareo M, Rosario Hernández Ibáñez M, Teruel Gila J. Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin. Med Clin (Barc) 2000; 115: 617-619
29. Michopoulos S, Tsibouris P, Bouzakis H, Balta A, Vougadiotis J, Broutet N, Kralios N. Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther 2000; 14: 737-744
30. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21-25